IRVINE, Calif. — Ambros Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new U.S. patent application covering methods of selectively treating patients having Complex Regional Pain Syndrome Type 1 (CRPS-1), an orphan designated disease. The granting of this...
Latest News
ALISO VIEJO, Calif. and MENLO PARK, Calif. — Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies’ selection by the University of California, Irvine (UCI)...
Philadelphia, PA – A study of more than 250 persons undergoing surgical therapy for Cushing’s disease (CD) or nonfunctioning pituitary adenomas (NFPAs) found that patients who achieved remission of CD were more likely than those with surgically treated NFPAs to develop new-onset autoimmune disease within 3 years after remission. The...
DALLAS, TX — Adults who reported drinking two liters (about 67 ounces) or more of sugar- or artificially sweetened drinks per week had a higher risk of an irregular heart rhythm known as atrial fibrillation compared with adults who drank fewer such beverages, according to new research published today in Circulation: Arrhythmia...
New York, NY – Specially packaged DNA secreted by tumor cells can trigger an immune response that inhibits the metastatic spread of the tumor to the liver, according to a study led by researchers at Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Korea’s Yonsei University. The discovery improves...
THOUSAND OAKS, Calif. — Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE® (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE). TEZSPIRE demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52....
THOUSAND OAKS, Calif. — Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon, executive vice...
THOUSAND OAKS, Calif. – Amgen (NASDAQ: AMGN) today announced the launch of Biomarker Assist™, a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on...
THOUSAND OAKS, Calif. – Amgen has mounted a comprehensive defense of its rare disease drug Tavneos as it seeks to prevent the FDA from withdrawing the therapy from the U.S. market over safety concerns. The company announced Friday that it had formally requested an FDA hearing after submitting a package...
THOUSAND OAKS, Calif. — Amgen announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s supplemental New Drug Application seeking full approval of LUMAKRAS® (sotorasib). This review, which resulted in a Complete Response Letter, was based on the CodeBreaK 200 trial results for...